{
  "docId": "019de075-89b3-76e0-854f-751e522d63c5",
  "docSlug": "a1e66a21a5f72ac122dd8f79d63b40d9",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 39,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "why_now",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a process-like flow to highlight the specific mechanism of action (IL-15/IL-21) compared to other approaches.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-89b3-76e0-854f-751e522d63c5/32",
  "deckHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5",
  "deckJsonHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5.json",
  "deckAnchorHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Potential to be a differentiated asset in celiac disease addressing both key inflammatory drivers: IL-15 and IL-21",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "161c6b55-e136-415c-b6f1-a1277650edca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.03,
        "y": 0.035
      },
      "kind": "diagram",
      "text": "Approaches to Treating Celiac Disease: gluten modification, restore gut barrier function, promote immune tolerance, reduce inflammation (IL-15/IL-21)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac681569-b738-49e7-808f-ebfff4b4b666",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.25,
        "x": 0.7,
        "y": 0.8
      },
      "kind": "disclaimer",
      "text": "FDA guidance was recently updated and provides clear guidelines for path to approval. Emphasis has been placed on development of effective anti-inflammatory strategies.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b77201e0-a386-478f-bed5-f5fe9bdea074",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.7,
        "y": 0.48
      },
      "kind": "image",
      "text": "Takeda, Pfizer, Anokion, ProventionBio",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6a92b95-9cd3-483c-a44a-5794d01431db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.35,
        "x": 0.28,
        "y": 0.74
      },
      "kind": "paragraph",
      "text": "IL-15 inhibition alone has shown efficacy in celiac disease, but results suggest that dual inhibition of IL-15 and IL-21 may have superior effect.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d905bb5-fa9b-457d-ba74-da93cee7bcdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.12,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "* https://www.fda.gov/media/157682/download",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8b4e6fe-675c-4e3a-af9a-9504f9741018",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.25,
        "x": 0.7,
        "y": 0.35
      },
      "kind": "title",
      "text": "Increasing Regulatory Clarity and Strategic Interest in Celiac Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "222ead40-62c3-4703-abb9-4efc997452fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Opportunity in Celiac Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fde44100-1515-4226-b1bf-9410f26f3995",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 33,
      "from": 32,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "9dba4129-78e2-4c77-b498-89d21b1c341b",
      "evidence": "The deck presents information on the potential for EQ102 in celiac disease",
      "position": 1,
      "objective": "Highlight the potential for EQ102 to be a differentiated asset in celiac disease",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}